Japan Research Develops Biosensor To Detect Stomach Cancer
This article was originally published in PharmAsia News
Executive Summary
Japanese scientists say they have developed a biosensor small enough to allow a physician to detect a gastrointestinal cancer through an endoscope. The researchers said the sensor on the end of the scope could eliminate the need for tests of blood or tissue samples that take days or weeks to determine the presence of a disease. The biosensor developed by a team at the National Institute of Advanced Industrial Science and Technology detects the presence of a growth factor released by cancer cells to feed a tumor, emitting a light that can be seen in the endoscope. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.